Long-term effect of high-dose dexamethasone with or without low-dose dexamethasone maintenance in untreated immune thrombocytopenia

Acta Haematologica

Volumn 133, Issue 1, 2015, Pages 124-128

  Din, Banhe ^a   Wang, Xingwen ^a   Shi, Yuye ^a   Li, Yufeng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

High dose dexamethasone; Immune thrombocytopenia; Long term efficacy; Maintenance therapy

Indexed keywords

DEXAMETHASONE; PREDNISONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISTRESS SYNDROME; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; IMMUNE THROMBOCYTOPENIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THROMBOCYTE COUNT; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PREDNISONE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925545863     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000362529     Document Type: Article

References (14)

1. McFarand J: Pathophysiology of platelet destruction in immune (idiopathic) thrombocytopenic purpura. Blood Rev 2002; 16: 1-2.
2. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A: Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-2554.
3. Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, Han ZC: Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005; 90: 914-923.
4. Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G: Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349: 831-836.
5. Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G: High-dose dexamethasone as a first-and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol 2004; 83: 764-768.
6. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, Vianelli N, Avvisati G, Rodeghiero F, Amendola A, Baronci C, Carbone C, Quattrin S, Fioritoni G, D'Alfonso G, Mandelli F; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party: Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109: 1401-1407.
7. Andersen JC: Response of resistant idiopathic thrombocytopenic purpura to pulsed highdose dexamethasone therapy. N Engl J Med 1994; 330: 1560-1564.
8. Warner M, Wasi P, Couban S, Hayward C, Warkentin T, Kelton JG: Failure of pulse high-dose dexamethasone in chronic idiopathic immune thrombocytopenia. Am J Hematol 1997; 54: 267-270.
9. Gutiérrez-Espíndola GR, Morales-Polanco MR, Guerrero-Rivera S, Talavera JO, Sánchez-Valle E, Gómez-Morales E, Gómez-Morales E, Pizzuto-Chávez J: High doses of dexamethasone in adult patients with idiopathic thrombocytopenic purpura. Arch Med Res 2003; 34: 31-34.
10. Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S: Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 2000; 26: 582-586.
11. Wali YA, Al Lamki Z, Shah W, Zacharia M, Hassan A: Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2002; 19: 329-335.
12. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393.
13. National Cancer Institute: Common Toxicity Criteria version 3.0. (CTCAE v3.0). 2003, http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3. pdf.
14. Buchanan GR, Adix L: Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141: 683-688.